3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Endometrial Neoplasms
1
ER+ HER2- Advanced Breast Cancer
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
Gemcitabine
13
Cisplatin
10
pembrolizumab
7
Oxaliplatin
5
Leucovorin
5
Fluorouracil
5
durvalumab
4
Paclitaxel
4
Nivolumab
3
Injections
3
Immune Checkpoint Inhibitors
3
Capecitabine
3
camrelizumab
2
Docetaxel
2
Cetuximab
2
Carboplatin
2
130-nm albumin-bound paclitaxel
2
tremelimumab
1
surufatinib
1
spartalizumab
1
silmitasertib
1
regorafenib
1
pertuzumab
1
manganese chloride
1
lenvatinib
1
irinotecan sucrosofate
1
folfirinox
1
devimistat
1
derazantinib
1
binimetinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Biliary Tract Neoplasms
×
AZD9833
×
Clear all
NCT04644068
2026-02-19
PETRA
AstraZeneca
Phase 1/2
Active not recruiting
702 enrolled